Compound ID | 3291

Update compound information

MK-7762 (TBD09)

Synonym(s): MK7762  |  MK 7762  |  TBD 09  |  TBD-09

Class: Oxazolidinone

Details of activity: Active against Mycobacterium tuberculosis; protein synthesis inhibitor (targets 50S ribosomal subunit)
Description: Synthetic compound
Institute where first reported: Bill & Melinda Gates Medical Research Institute; Merck
Year first mentioned: 2023
Highest developmental phase: Phase 1 (NCT05824091)
Development status: Active (as of 2024)
Chemical structure(s):
Click here for structure editor
Molecular weight: 419.4
Iso. SMILES: COC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C(=C2)F)N3CCS(=O)(=O)CC3)F
InChI Key: CCYKSCLMFZLAJH-NSHDSACASA-N
Can. SMILES: COC(=O)NC[C@H]1CN(C2=CC(=C(C(=C2)F)N3CCS(=O)(=O)CC3)F)C(=O)O1
InChI: InChI=1S/C16H19F2N3O6S/c1-26-15(22)19-8-11-9-21(16(23)27-11)10-6-12(17)14(13(18)7-10)20-2-4-28(24,25)5-3-20/h6-7,11H,2-5,8-9H2,1H3,(H,19,22)/t11-/m0/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/156857753
Guide to Pharmacology: MK-7762
Citation: https://www.newtbdrugs.org/pipeline/compound/tbd09-mk7762

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.